Approximately 15% of patients with early-stage HER2-positive breast cancer experience a recurrence after adjuvant treatment with trastuzumab, and patients with advanced HER2-positive breast cancer who are treated palliatively with trastuzumab tend to show disease progression within one year5. This evidence concerns the gene ERBB2 and breast cancer.